AbZelect™ and AbZelectPRO™ cell line development platforms
AbZelect™ and AbZelectPRO™ support cell line development (CLD) to rapidly progress therapeutic protein and recombinant vaccine projects while de-risking the journey to Investigational New Drug (IND) application.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Designed for traditional protein programs, such as antibodies, Abzena’s proprietary, license-free AbZelect™, is optimized across the three key areas of vector, host cell line, and process. It provides improved cell doubling times, viable cell densities, and robust and stable cell lines.
The AbZelectPRO™ platform combines AbZelect™ with 2G UNic® premium vector technology to boost expression levels and generate higher-producing, stable cell lines expressing proteins including bispecifics, fusions, and other novel modalities.
By streamlining the CLD process, the AbZelect™ platforms can progress your project from sequencing to research cell banks in 15 weeks, helping to deliver your project to the clinic faster.
Our AbZelect™ platforms promote the in-depth characterization of multiple candidates at early stages through the generation of multiple fast stable pools, enabling rapid identification and mitigation of risk.
